Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

Description

To evaluate progression of metastatic renal cell carcinoma from the initiation of PULSAR radiotherapy in combination with IMSA101 injectable onward.

Conditions

Metastatic Renal Cell Carcinoma ( mRCC), OligoProgressive Metastatic Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

To evaluate progression of metastatic renal cell carcinoma from the initiation of PULSAR radiotherapy in combination with IMSA101 injectable onward.

STING Agonist and Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer (SPARK)

Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

Condition
Metastatic Renal Cell Carcinoma ( mRCC)
Intervention / Treatment

-

Contacts and Locations

Dallas

University of Texas Southwestern Medical Center, Dallas, Texas, United States, 75390

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients must have metastatic ccRCC.
  • * Patients must have oligoprogression defined as progression in ≤3 lesions.
  • * All oligoprogression lesions must be suitable for radiation.
  • * Patients must have at least one site of disease that can be safely injected with IMSA101. Lung metastases are excluded.
  • * ECOG performance status 0-2.
  • * Age ≥ 18 years.
  • * Patients must have adequate organ and marrow function within 14 days prior to study entry.
  • * All IMDC risk categories are allowed.
  • * Patients with progressive ultracentral/central chest lesions will be excluded

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Texas Southwestern Medical Center,

RAQUIBUL HANNAN, MD, PRINCIPAL_INVESTIGATOR, University of Texas Southwestern Medical Center

Study Record Dates

2028-10